Health
CARB-X funds Phico to develop new intravenous engineered bacteriophage drug – The Pharma Letter
Global non-profit partnership CARB-X is funding privately-held UK company Phico Therapeutics to develop a new intravenous engineered bacteriophage drug to treat
Global non-profit partnership CARB-X is funding privately-held UK company Phico Therapeutics to develop…To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space.
Or, if you’re only interested in reading the content about a specific topic (M&A, coronavirus/COVID-19, pricing, reimbursement and access, outsourcing, CRO…
-
Noosa News22 hours agoThe Laundry Lady secures $1M to fuel international expansion
-
Noosa News19 hours agoTruffle growers say rare delicacy is worth its $3,500 per kilo expense
-
Noosa News12 hours agoWhere, when and why? Everything you need to know about Sunday’s pro-Palestine protest march in Brisbane
-
Noosa News19 hours agoHomicide investigation underway after woman found dead in north Brisbane